NelsonDKodsiMCockrellD,et al.Thrombotic thrombocytopenic purpura associated with pembrolizumab. J Oncol Pharm Pract2022. doi: 1177/10781552211073883 (epub ahead of print 17 January 2022)
2.
HayataMShimanukiMKoT, et al.Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review. Ren Replace Ther2020; 6: 29.
3.
MoakeJL. Thrombotic microangiopathies. N Engl J Med2002; 347: 589–600.
De FilippisSMooreCEzellK,et al.Immune checkpoint inhibitor-associated thrombotic thrombocytopenic purpura in a patient with metastatic non-small-cell lung cancer. Cureus2021; 13: e16035.
GergiMLandryKKAdesS, et al.Nivolumab-induced thrombotic thrombocytopenic purpura in a patient with anal squamous cell carcinoma: a lesson on hematologic toxicity from immunotherapy. Oncologist2020; 25: 1009–1012.
8.
YoussefAKassoNTorloniAS, et al.Thrombotic thrombocytopenic purpura due to checkpoint inhibitors. Case Rep Hematol2018; 2018: 2464619.
9.
LanfranchiASpringeDRuppA, et al.Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma. CEN Case Rep2020; 9: 289–290.
10.
LancelotMMillerMJRobackJ, et al.Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy. Transfusion2021; 61: 322–328.
11.
MunizTPPatriquinCJSaibilSD. Presumed compliment-mediated, checkpoint inhibitor-induced, thrombotic microangiopathy in a patient with metastatic melanoma. BMJ Case Rep2021; 14: e242075.
12.
GilbarPJDavisMRDosing of PD-1 and PD-L1 inhibitors: cost saving initiatives for significantly decreasing associated expenditure. J Oncol Pharm Pract2021; 27: 199–204.
